{"id":692773,"date":"2022-10-06T07:23:11","date_gmt":"2022-10-06T11:23:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\/"},"modified":"2022-10-06T07:23:11","modified_gmt":"2022-10-06T11:23:11","slug":"compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\/","title":{"rendered":"Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<ul type=\"disc\">\n<li>Clinical data from dual combination COM701\/nivolumab MSS-CRC cohort expansion study<\/li>\n<li>Research data on differentiation of PVRIG from other immune checkpoints<\/li>\n<\/ul>\n<p>\n        <span class=\"legendSpanClass\">HOLON, <span class=\"xn-location\">Israel<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Oct. 6, 2022<\/span><\/span> \/PRNewswire\/ &#8212; <a href=\"http:\/\/www.cgen.com\/\" target=\"_blank\" rel=\"nofollow noopener\">Compugen Ltd.<\/a>\u00a0(Nasdaq: CGEN), a clinical-stage cancer immunotherapy\u00a0company and a pioneer in computational target discovery, announced today\u00a0that it will present new clinical data from its dual combination COM701\/nivolumab MSS-CRC cohort expansion study and research data on the differentiation of PVRIG from other immune checkpoints in two oral presentations at the 37<sup>th<\/sup> Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place between <span class=\"xn-chron\">10-12 November 2022<\/span>, Boston,\u00a0MA.\u00a0<\/p>\n<p>\n        <b>Oral presentation details:<\/b>\n      <\/p>\n<p>\n        <b>Title:<\/b>\u00a0COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases<\/p>\n<p>\n        <b>Abstract Number:<\/b> 659<\/p>\n<p>\n        <b>Session Title: \u00a0<\/b>Clinical Development of Novel Checkpoint Inhibitors<\/p>\n<p>\n        <b>Session Date<\/b>\u00a0Thursday, November 10, 2022, <span class=\"xn-chron\">6:45pm ET<\/span><\/p>\n<p>\n        <b>Title: <\/b>PVRIG, a novel T cell checkpoint, is preferentially expressed in TLS on stem-like memory T cells, potentially inhibiting their expansion\u00a0<\/p>\n<p>\n        <b>Abstract Number:<\/b> 504<\/p>\n<p>\n        <b>Session Title:<\/b> Next Generation Checkpoint Blockade: Mechanisms of Action<\/p>\n<p>\n        <b>Session Date: <\/b><br \/>\n        <span class=\"xn-chron\">Friday, November 11, 2022<\/span>, <span class=\"xn-chron\">5:20pm ET<\/span><\/p>\n<p>Compugen&#8217;s presentations will be available on the publications section of Compugen&#8217;s website, <a href=\"http:\/\/www.cgen.com\" rel=\"nofollow\">www.cgen.com<\/a> following presentation.<\/p>\n<p>\n        <b>About\u00a0Compugen <\/b>\n      <\/p>\n<p>Compugen\u00a0is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies.\u00a0Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902,\u00a0a potential best-in-class monoclonal antibody targeting TIGIT for the treatment of solid tumors. Partnered programs include bapotulimab, an antibody targeting ILDR2, in Phase 1 development, licensed to Bayer under a research and discovery collaboration and license agreement, and a TIGIT\/PD-1 bispecific derived from COM902 (AZD2936) in Phase 1\/2 development by AstraZeneca through a license agreement for the development of bispecific and multi-specific antibodies.\u00a0In addition, the Company&#8217;s therapeutic pipeline of early-stage\u00a0immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets. The most advanced program, COM503 is about to enter pre-IND enabling studies.\u00a0COM503 is a potential first-in-class, high affinity antibody targeting cytokine biology to enhance anti-tumor immunity in a differentiated manner. Compugen\u00a0is headquartered in <span class=\"xn-location\">Israel<\/span>, with offices in South San Francisco, CA.\u00a0Compugen&#8217;s\u00a0shares are listed on Nasdaq and the Tel Aviv\u00a0Stock Exchange under the ticker symbol CGEN.<\/p>\n<p>\n        <b>Company contact:<br \/><\/b><br \/>\n        <span class=\"xn-person\">Yvonne Naughton<\/span>, Ph.D.<br \/>Head of Investor Relations and Corporate Communications<br \/>Email:\u00a0<a href=\"mailto:elanah@cgen.com\" target=\"_blank\" rel=\"nofollow noopener\">ir@cgen.com<\/a><br \/>Tel: +1\u00a0(628)\u00a0241-0071\u00a0\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN90899&amp;sd=2022-10-06\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow noopener\" href=\"https:\/\/www.prnewswire.com\/news-releases\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022-301641798.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022-301641798.html<\/a><\/p>\n<p>SOURCE  Compugen Ltd.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LN90899&amp;Transmission_Id=202210060700PR_NEWS_USPR_____LN90899&amp;DateId=20221006\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Clinical data from dual combination COM701\/nivolumab MSS-CRC cohort expansion study Research data on differentiation of PVRIG from other immune checkpoints HOLON, Israel, Oct. 6, 2022 \/PRNewswire\/ &#8212; Compugen Ltd.\u00a0(Nasdaq: CGEN), a clinical-stage cancer immunotherapy\u00a0company and a pioneer in computational target discovery, announced today\u00a0that it will present new clinical data from its dual combination COM701\/nivolumab MSS-CRC cohort expansion study and research data on the differentiation of PVRIG from other immune checkpoints in two oral presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place between 10-12 November 2022, Boston,\u00a0MA.\u00a0 Oral presentation details: Title:\u00a0COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-692773","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Clinical data from dual combination COM701\/nivolumab MSS-CRC cohort expansion study Research data on differentiation of PVRIG from other immune checkpoints HOLON, Israel, Oct. 6, 2022 \/PRNewswire\/ &#8212; Compugen Ltd.\u00a0(Nasdaq: CGEN), a clinical-stage cancer immunotherapy\u00a0company and a pioneer in computational target discovery, announced today\u00a0that it will present new clinical data from its dual combination COM701\/nivolumab MSS-CRC cohort expansion study and research data on the differentiation of PVRIG from other immune checkpoints in two oral presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place between 10-12 November 2022, Boston,\u00a0MA.\u00a0 Oral presentation details: Title:\u00a0COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases &hellip; Continue reading &quot;Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-06T11:23:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN90899&amp;sd=2022-10-06\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022\",\"datePublished\":\"2022-10-06T11:23:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\\\/\"},\"wordCount\":433,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LN90899&amp;sd=2022-10-06\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\\\/\",\"name\":\"Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LN90899&amp;sd=2022-10-06\",\"datePublished\":\"2022-10-06T11:23:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LN90899&amp;sd=2022-10-06\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LN90899&amp;sd=2022-10-06\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\/","og_locale":"en_US","og_type":"article","og_title":"Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022 - Market Newsdesk","og_description":"PR Newswire Clinical data from dual combination COM701\/nivolumab MSS-CRC cohort expansion study Research data on differentiation of PVRIG from other immune checkpoints HOLON, Israel, Oct. 6, 2022 \/PRNewswire\/ &#8212; Compugen Ltd.\u00a0(Nasdaq: CGEN), a clinical-stage cancer immunotherapy\u00a0company and a pioneer in computational target discovery, announced today\u00a0that it will present new clinical data from its dual combination COM701\/nivolumab MSS-CRC cohort expansion study and research data on the differentiation of PVRIG from other immune checkpoints in two oral presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place between 10-12 November 2022, Boston,\u00a0MA.\u00a0 Oral presentation details: Title:\u00a0COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases &hellip; Continue reading \"Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-06T11:23:11+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN90899&amp;sd=2022-10-06","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022","datePublished":"2022-10-06T11:23:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\/"},"wordCount":433,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN90899&amp;sd=2022-10-06","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\/","name":"Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN90899&amp;sd=2022-10-06","datePublished":"2022-10-06T11:23:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN90899&amp;sd=2022-10-06","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN90899&amp;sd=2022-10-06"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692773","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=692773"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692773\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=692773"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=692773"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=692773"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}